Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05125302 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
A Phase 3 study of Migraine, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,059
- Enrollment target
- 20
- Study locations
NCT05125302: Recruiting Phase 3 study of Migraine, sponsored by AbbVie.
NCT05125302 is a Phase 3 study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 1,059 participants, above the 348-participant average among 102 other Migraine trials with a reported enrollment target (204% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05125302, a Phase 3 study of Migraine, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,059 participants
- Enrollment target
- 20
- Study locations
Study Summary
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis to determine dose selection for the main study. In the main study, after dose selection, children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo. Adolescents aged 12-17 years will be randomized to receive either low or high dose of Ubrogepant or placebo with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will receive oral tablets of the double-blind study intervention. There will be an option to take a second dose of double-blind study intervention (identical to initial dose), or rescue medication, at least 2 hours after the initial dose, for headache of moderate/severe intensity. Around 1059 participants will be enrolled in the study in approximately 120 sites in the United States. The study duration will be up to 6 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Primary Outcome
Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.
Conditions Studied
Interventions
- DRUG Ubrogepant
- DRUG Placebo-Matching Ubrogepant
Study Locations (20)
California
- Advanced Research Center /ID# 227962 - Anaheim
- Neuro Pain Research Center /ID# 227966 - Fresno
- Alliance for Research Alliance for Wellness /ID# 230546 - Long Beach
- Children's Hospital Los Angeles /ID# 230596 - Los Angeles
- Excell Research, Inc /ID# 230899 - Oceanside
- Paradigm Clinical Research - San Diego /ID# 269608 - San Diego
- Lumos Clinical Research Center /ID# 231267 - San Jose
- Pacific Clinical Research Management Group /ID# 231636 - Upland
- Sunwise Clinical Research /ID# 230971 - Walnut Creek
- Amicis Research Center /ID# 272621 - Winnetka
Arkansas
- HealthStar Research Glenwood /ID# 275303 - Glenwood
- HealthStar Research of Hot Springs PLLC /ID# 273256 - Hot Springs
- Preferred Research Partners /ID# 230725 - Little Rock
Colorado
- Children's Hospital Colorado - Aurora /ID# 231879 - Aurora
- IMMUNOe Research Centers /ID# 230879 - Centennial
- MCB Clinical Research Centers /ID# 231625 - Colorado Springs
Alabama
- Rehabilitation & Neurological Services /ID# 229969 - Huntsville
- The Center for Clinical Trials - Saraland /ID# 231546 - Saraland
Arizona
- Velocity Clinical Research - Phoenix /ID# 274478 - Phoenix
Connecticut
- New England Institute for Clinical Research /ID# 230635 - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,059 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What NCT05125302 shows while recruiting
NCT05125302 is an interventional study that assigns participants to a tested intervention. Its 1,059 participants enrollment target places it among the larger protocols in the corpus, above the 348-participant average among 102 other Migraine trials with a reported enrollment target (204% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Ubrogepant is the first listed.
NCT05125302 names 20 study sites across 6 states, led by California, Arkansas, Colorado.
Frequently Asked Questions
What is clinical trial NCT05125302 about?
NCT05125302 is a clinical study titled "Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)". Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how sa...
What is the current status of trial NCT05125302?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,059 participants. The study started on 2022-01-13. Estimated completion is 2026-05.
What conditions does trial NCT05125302 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05125302?
The interventions under investigation include: Ubrogepant (DRUG), Placebo-Matching Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT05125302?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05125302 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05125302's enrollment target sits among peer trials
1,059 10th of 102 higher than 93 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
-
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI